Fourteen modules. Twelve stages.Intelligence at every decision.

The persistent, compounding intelligence layer beneath every module. Not a database — an intelligence substrate that gets sharper with every interaction. When 11 people turn over in a year, it retains every decision, every competitive signal, every strategic insight. The second module compounds on the first. By the fifth, it's irreplaceable.

Before a molecule enters a single patient, this module generates synthetic patient populations and disease models to explore the target population, model disease progression, and identify patient subgroups that change the economics of the entire program.

Continuous monitoring of the competitive and regulatory landscape during development. When a competitor posts a Phase I entry targeting your mechanism, you know that week. Signal convergence — hiring patterns, patent filings, and trial changes — reveals competitor strategy before they announce it.

Before committing to a pivotal trial architecture, simulate it. Trial Design Optimization takes competitive context from Competitive & Regulatory Intelligence and population insights from Synthetics & Phenotype Intelligence and applies them to the most expensive design decision in the lifecycle — the Phase III pivotal trial.

The connective tissue between clinical investment and commercial return. Every claim traces to evidence, every gap is identified, every requirement is tracked from protocol through clinical study report to label. Automated evidence sufficiency scoring across regulators, payers, and key opinion leaders.

Continuous monitoring of supply chain vulnerabilities — active pharmaceutical ingredient supplier health, excipient availability, cold chain logistics, contract manufacturer capacity, and demand signals. The difference between proactive mitigation and reactive crisis management.

Replaces months-long market research with synthetic audiences that deliver comparable insight in days. Synthetic healthcare professional panels, patient panels, payer panels, and key opinion leader panels — 20 message variations tested instead of 2, at a fraction of the cost.

Full messaging architecture grounded in the molecule's actual competitive reality and evidence base. Strategic positioning, brand narrative, messaging pillars, core claims — all evidence-grounded and Medical-legal-regulatory review-ready with complete traceability.

Models what matters to the people who decide whether patients can actually access your product. Formulary access prediction, net price modeling, Incremental cost-effectiveness ratio threshold analysis, and payer evidence requirements — the bridge between clinical investment and commercial return.

In-market intelligence that transforms reactive competitor tracking into proactive competitive strategy. War gaming simulations, congress monitoring, biosimilar early warning — signal classification that separates noise from what demands response.

Monitors adverse event databases, complaint systems, literature, and social signals for emerging safety issues before they reach regulatory thresholds. Signal classification into action recommendations — monitor, investigate, escalate, act.

Identifies and evaluates extension opportunities — and prioritizes them against the competitive landscape you're actually facing. Indication expansion, formulation assessment, pediatric strategy, and return-on-investment modeling under various competitive scenarios.

When the stakes are measured in billions, timing precision is measured in weeks. Generic and biosimilar filing surveillance, authorized generic scenario modeling, franchise defense strategies, and pharmacy benefit manager switching threshold modeling under simultaneous biosimilar entry.

The portfolio-level view — tracking lifecycle position across every product to identify timing, triggers, and allocation priorities. Decision debt identification reveals where decisions are overdue and what the compounding cost of deferral is.